The GLP-1 drug market is expanding rapidly as diabetes and obesity create sustained demand for therapies that support glycemic management and weight-related care. The market was valued at USD 10.77 billion in 2024, is estimated at USD 12.19 billion in 2025, and is projected to reach USD 42 billion by 2035, growing at a CAGR of 13.17%.marketresearchfuture

GLP-1 therapies are increasingly important in the treatment landscape for type 2 diabetes, which represents the largest indication segment with approximately 52% market share. Obesity is a faster-growing application area as healthcare systems and consumers place greater focus on long-term weight management and metabolic health.

Long-acting GLP-1 therapies dominate the drug-type segment, holding around 57% market share. Their position is supported by the convenience of less frequent dosing and growing preference for treatment approaches that may help improve patient persistence. Short-acting and dual-action products also contribute to the market as companies develop therapies for different patient needs and clinical objectives.

Subcutaneous injection remains the leading administration route, accounting for about 64% of the market. However, oral GLP-1 therapies are gaining attention because many patients prefer non-injectable treatment options. The availability of oral formulations could broaden adoption in primary-care settings and support patients who may be reluctant to use injections.

Retail pharmacies are important for treatment access, while hospital pharmacies continue to play a major role for patients receiving specialized care. Online pharmacy channels are expected to grow as digital healthcare, home delivery, telemedicine, and chronic-care platforms become more common.

North America leads the market with more than 50% of global revenue, supported by high diabetes prevalence, reimbursement mechanisms, advanced healthcare infrastructure, and strong pharmaceutical innovation. Key companies include Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, AstraZeneca, Merck & Co., Bristol Myers Squibb, and Amgen.marketresearchfuture

Read more: GLP-1 Drug Market

People Also Ask

Q1. What are GLP-1 drugs used for?
They are used primarily in type 2 diabetes care and are increasingly used within obesity and metabolic-health treatment pathways.

Q2. Why is the GLP-1 drug market growing quickly?
Diabetes and obesity prevalence, innovation in drug delivery, patient awareness, and wider treatment adoption are key drivers.

Tags: GLP-1 drug market, type 2 diabetes treatment, obesity management, metabolic health, GLP-1 therapies